Prozone effect of serum IgE levels in a case of plasma cell leukemia

Giampaolo Talamo, William Castellani, Nathan G. Dolloff

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to therapy.

Original languageEnglish (US)
Article number32
JournalJournal of Hematology and Oncology
Volume3
DOIs
StatePublished - Sep 16 2010

Fingerprint

Plasma Cell Leukemia
Immunoglobulin E
Serum
Myeloma Proteins
Stem Cell Transplantation
Tumor Biomarkers
Antigen-Antibody Complex
Multiple Myeloma
Proteinuria
Electrophoresis
Immunoglobulins
Blood Proteins
Reference Values
Light
Antigens
Drug Therapy
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Talamo, Giampaolo ; Castellani, William ; Dolloff, Nathan G. / Prozone effect of serum IgE levels in a case of plasma cell leukemia. In: Journal of Hematology and Oncology. 2010 ; Vol. 3.
@article{12083d96b69e4a54ac9cb9d11fd9f4d2,
title = "Prozone effect of serum IgE levels in a case of plasma cell leukemia",
abstract = "We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to therapy.",
author = "Giampaolo Talamo and William Castellani and Dolloff, {Nathan G.}",
year = "2010",
month = "9",
day = "16",
doi = "10.1186/1756-8722-3-32",
language = "English (US)",
volume = "3",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",

}

Prozone effect of serum IgE levels in a case of plasma cell leukemia. / Talamo, Giampaolo; Castellani, William; Dolloff, Nathan G.

In: Journal of Hematology and Oncology, Vol. 3, 32, 16.09.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prozone effect of serum IgE levels in a case of plasma cell leukemia

AU - Talamo, Giampaolo

AU - Castellani, William

AU - Dolloff, Nathan G.

PY - 2010/9/16

Y1 - 2010/9/16

N2 - We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to therapy.

AB - We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=77956490377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956490377&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-3-32

DO - 10.1186/1756-8722-3-32

M3 - Article

C2 - 20828419

AN - SCOPUS:77956490377

VL - 3

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 32

ER -